A significant amount of secondary sources, directories, and databases were used in this market research study in order to locate and gather data relevant to this technical, financial, and market-oriented analysis of the worldwide biomarkers market. In order to gather and validate crucial qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were carried out with a variety of primary respondents, including important industry participants, subject-matter experts (SMEs), C-level executives of significant market players, and industry consultants, among other experts. To get the ultimate market size, the worldwide biomarkers market's size—which was approximated using a variety of secondary research techniques—was triangulated with data from primary research.
An immunoassay is a biochemistry-based test used to determine if an analyte is present or concentrated. A big protein or antibody that is created as a result of an infection can be an analyte. Immunoassays are now widely used and recognised laboratory protocols. They deliver exact and accurate results fast and effortlessly. The main applications of this approach are in food testing, drug discovery, clinical diagnostics, and drug monitoring.
The market was divided into a number of segments and sub-segments once the overall market size was determined utilising the market size estimation procedures. Data triangulation and market breakdown processes were used when appropriate to finish the entire market engineering process and obtain the precise statistics of each market segment and subsegment. By examining numerous variables and patterns from the immunoassays industry's supply and demand sides, the data was triangulated.
o US
o Canada
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
o Brazil
o Argentina
o Rest of South America
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
The market for immunoassay has expanded significantly as a result of technology developments. For quicker testing and outcomes, automated laboratory apparatus has been designed. Labour and space requirements are decreased and laboratory efficiency is increased by automation. Because some players provide small, portable automated laboratory systems and point-of-care testing, the industry is growing quickly as a result.
Research laboratories, especially biotechnology labs, should catch up with their counterparts in diagnostics in terms of automated immunoassay implementation, and they should also become more familiar with the development of diagnostic apparatus. Every industry, including healthcare, is becoming more automated. Automated immunoassays, for example, offer increased assay transfer, reproducibility, and throughput.
Reduction in time and operator dependence on unpredictability are the two benefits of this method. In the US, Siemens Healthcare Diagnostic, for example, provides five completely automated immunoassay platforms.
In 2022, the immunoassay market was dominated by the kit and reagent category, which held a market share of over 61%. During the projected period, the sector is anticipated to lead the market. There is a growing need for immunoassay kits and reagents for diagnostic applications due to the rising incidence of autoimmune and infectious disorders. Additionally, immunoassay kit approval and distribution are anticipated to support segment expansion.
In 2022, the immunoassay market was dominated by the ELISA category, which held a market share of over 61%. This method has several advantages over immunoelectrophoretic and immunodiffusion, such as antiserum analysis, faster test periods, and qualitative and qualitative results.
The rising incidence of cancer cases around the world is the main reason boosting the immunoassay market over the predicted period. The International Agency for Research on Cancer projected that there will be over 18.2 million new cases of cancer worldwide in 2020, and that the disease will cause over 10 million deaths. Therefore, it is anticipated that a rise in cancer incidence will increase the use of immunoassays.
The immunoassay market is divided into end-user segments based on the following: blood banks, clinical labs, pharmaceutical & biotechnology firms, hospitals & clinics, research & academic laboratories, CROs, and home care settings. With a 31% market share in 2022, the hospital & clinical segment will have a dominant position in the immunoassay industry. The hospital segment is growing quickly as a result of the rise in hospital numbers.